Benzinga | May 21, 2021 12:49PM EDT

Looking Into UroGen Pharma's Return On Capital Employed

UroGen Pharma (NASDAQ:URGN) reported Q1 sales of $7.49 million. Earnings fell to a loss of $26.11 million, resulting in a 4.18% decrease from last quarter. In Q4, UroGen Pharma brought in $7.97 million in sales but lost $27.25 million in earnings.

What Is ROCE?

Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q1, UroGen Pharma posted an ROCE of -0.34%.

Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.

Return on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders.

For UroGen Pharma, the return on capital employed ratio shows the current amount of assets may not actually be helping the company achieve higher returns, a note many investors will take into account when making long-term financial decisions.

Q1 Earnings Insight

UroGen Pharma reported Q1 earnings per share at $-1.17/share, which beat analyst predictions of $-1.29/share.